Meyka Pro banner
Keymed Biosciences Inc.

Keymed Biosciences Inc. (2162.HK) Stock Competitors & Peer Comparison

See (2162.HK) competitors and their performances in Stock Market.

2162.HKHKSE
HealthcareBiotechnology
HK$85.35
HK$1.65(1.90%)
Hong Kong Market is Open · 15:51

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2162.HKHK$81.65-5.00%24.1B-38.65-HK$2.11N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$185.60-2.73%250.3B83.91HK$2.21N/A
1801.HKHK$88.95-5.57%154.9B163.57HK$0.54N/A
2269.HKHK$36.98-5.95%153.2B28.94HK$1.28N/A
6990.HKHK$486.40-6.91%113.4B-241.15-HK$2.02N/A
9926.HKHK$88.35-13.21%81.3B-65.86-HK$1.34N/A
3347.HKHK$36.70-6.47%44.5B37.56HK$0.98+0.39%
6821.HKHK$117.20-8.94%42.3B38.43HK$3.05+1.28%
1530.HKHK$16.15-9.83%40.4B4.21HK$3.84+1.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2162.HK vs 4332.HK Comparison July 2026

2162.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2162.HK stands at 24.1B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2162.HK is priced at HK$81.65, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2162.HK currently has a P/E ratio of -38.65, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2162.HK's ROE is -0.17%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2162.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2162.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions